According to the study conducted by the University of Oxford, a common drug used to treat asthma, can help fasten the process of recovery in COVID-19 patients. The study published in the Lancet journal found that inhaled glucocorticoids can reduce the risk of severe COVID and hospitalisation amongst people infected with SARs-COV-2 infections.
Similarly, earlier studies from China, Italy and other countries had suggested the same claiming patients with asthma and chronic obstructive pulmonary disease (COPD) were less likely to be hospitalised.
Can inhaled budesonide ensure shorter recovery period?
The Lancet study involved 146 participants from the United Kingdom, half of whom were asked to use inhalers with budesonide and received the COVID care.
The team of researchers found that inhaled budesonide, when given in regulated doses and for a short period of time, could be effective in treating severe COVID and could also ensure a shorter recovery period.
Additionally, it was found that the duration of fever in COVID patients was much lower in the group that received the budesonide as compared to those who were only limited to the usual care group.
Patients who received inhaled budesonide reported less signs of persistent Covid-19 symptoms beyond 14 days.
The conclusive report suggested that inhaled budesonide reduced the probability of hospitalisation and also reduced the risk of severe infections in COVID-19 patients.